NCT07144527View on ClinicalTrials.gov

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

November 1, 2026

Conditions
AgingFrailtyExercise ToleranceHealthy Male and Female Subjects
Interventions
DIETARY_SUPPLEMENT

NMN, betaine, low-dose hydrogen peroxide (EGA)

Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.

DIETARY_SUPPLEMENT

Nicotinamide Mononucleotide (NMN)

Conventional NMN supplement.

DIETARY_SUPPLEMENT

Placebo

Organoleptically matched inert control.

Trial Locations (1)

90210

RECRUITING

Medical Office of Dr. Robert Huizenga MD, Beverly Hills

Sponsors

Collaborators (1)

EGACeutical
All Listed Sponsors
collaborator

Concordia University Chicago

OTHER

collaborator

EGACeutical

UNKNOWN

lead

Scott Silveira

OTHER

NCT07144527 - Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults | Biotech Hunter | Biotech Hunter